Aim: Creation of a single indicator of access to medicines. Methods: Data collection was
performed with individuals who obtained their medication from either public and/or private …

Enforcement includes regulations by law. Examples include restricting the prescribing of
certain medicines to second line due to concerns with their value, eg, patented versus …

Drug budget and prescription control measures are implemented regionally in Germany,
meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region. We …

There are a number of ongoing developments to improve the care of patients with diabetes
across countries given its growing burden. Recent developments include new oral …

Introduction Infliximab (IFX) biosimilars are available to treat inflammatory bowel disease
(IBD), offering cost reductions versus originator IFX in some jurisdictions. However, concerns …

Objective The market entry of biosimilars is expected to bring budgetary relief. Our objective
was to determine how the introduction of biosimilars influences medication costs in patients …

Introduction Although there is a significant utilization gap of biologic medicines in the EU,
many studies estimate equity in patient access to biopharmaceuticals only based on their …

Hyperactivity of the immune system in the gastrointestinal tract leads to the development of
chronic, inflammation-associated disorders. Such diseases, including inflammatory bowel …

The advent of biologic therapy has made it possible to set new standards of efficacy and
safety in the treatment of moderate to severe psoriasis, which are far reaching and uniformly …

Study Objectives: Different policies have been implemented to enhance uptake of
biosimilars. Regarding policies focussing on the demand-side, the literature has mainly …